The role of comorbidity in the management of patients with combined pathology of asthma and copd

Authors

  • Ksenia Nazarenko SO “National institute of phthisiology and pulmonology named after F. G. Yanovskyi NAMSof Ukraine” M. Amosova str., 10, Kyiv, Ukraine, 03141, Ukraine https://orcid.org/0000-0003-2116-2693

DOI:

https://doi.org/10.15587/2519-4798.2017.108065

Keywords:

combined bronchial obstructive pathology, comorbidity, prognosis, external breath function, inflammation

Abstract

The aim of the study was the revelation of the comorbidity influence in patients with the combined pathology of bronchial asthma and chronic obstructive pulmonary disease on clinical manifestations and symptoms of the disease, system inflammation factors and breath functional parameters.

Materials and methods. The study included 140 patients with the combined bronchial obstructive pathology of the mean age 58,56±0,81 years, 74 women, 66 men.

All patients underwent the spirometry and bodypletizmography (“Master Screen PFT”, Germany). The test with 6-minutes walking was realized according to the standard protocol. The determination of the clinical course severity and disease prognosis was assessed by BODE index. All patients underwent the clinical analysis of blood, coagulogram, determination of highly-specific C-reactive protein. The level of dyspnea was assessed in all patients by the modified scale of the medical research council (mMRC), and also the index of basic dyspnea (BDI). The general point by the Charlson comorbidity index was calculated for all patients.

Results. With the increase of the number of concomitant diseases, the intensity of symptoms and functional disorders, inherent to bronchial asthma and chronic obstructive pulmonary disease increased. At the high level of comorbidity index, dyspnea was reliably more essential (by mMRC) comparing with one of patients with the low and middle level of comorbidity (p<0,05); functional disorders were more intense, realization of a usual activity was complicated (by BDI). Patients with the combined bronchial obstructive pathology with the high comorbidity level had the decreased physical tolerance (in the test with 6-minutes walking) and also reliably worse disease prognosis (higher BODE-index).

The increase of comorbidity index was attended by negative changes of volumes, capacities, parameters of bronchial permeability at all levels of respiratory tracts in patients with the combined bronchial obstructive pathology.

Patients with the combined pathology with the high comorbidity index had reliably higher indicators of the system inflammation (С-reactive protein, fibrinogen) comparing with patients with the middle and low comorbidity indices (р<0,05). Patients with the middle comorbidity level had the reliably higher content of neutrophils of peripheral blood comparing with one of patients with the low comorbidity (р<0,05).

Conclusions. Patients with the combined brionchial obstructive pathology at additional comorbid diseases demonstrated the essential intensification of clinical manifestations and symptoms of the disease, worsening of external breath function indices, intensification of the system inflammation and prognosis worsening. The combination of diseases played also rather important role at the combined bronchial obstructive pathology

Author Biography

Ksenia Nazarenko, SO “National institute of phthisiology and pulmonology named after F. G. Yanovskyi NAMSof Ukraine” M. Amosova str., 10, Kyiv, Ukraine, 03141

PhD

Department of Pulmonology 

References

  1. Zhang, M., Holman, C. D. J., Price, S. D., Sanfilippo, F. M., Preen, D. B., Bulsara, M. K. (2009). Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study. BMJ, 338 (3), 2752–2752. doi: 10.1136/bmj.a2752
  2. Vyortkina, A., Skotnikov, A. (2013). Komorbidnost. Lechashchiy vrach, 8, 34–38.
  3. Naumova, L., Osipova, O. (2016). Komorbidnost: mehanizmy ipatogeneza, klinicheskoe znachenie. Sovremennyie problemy nauki i obrazovaniya, 5. Available at: https://www.science-education.ru/ru/article/view?id=25301
  4. Charlson, M. E., Pompei, P., Ales, K. L., MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases, 40 (5), 373–383. doi: 10.1016/0021-9681(87)90171-8
  5. Feschenko, Yu. I. (2015). Bronhialna astma, hronichne obstruktivne zahvoryuvannya legen: perspektivna globalna strategiya vedennya, novitni metodi diagnostiki, suchasni pidhodi do terapiyi. Astma ta alergiya, 4, 38–42.
  6. Papaiwannou, A., Zarogoulidis, P., Porpodis, K. et. al. (2014). Asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS): current literature review. Journal of Thoracic Disease, 6, 146–151.
  7. Lapach, S. N., Chubenko, A. B., Babich, P. N. (2000). Statisticheskie metodyiv mediko–biologicheskih issledovaniyah s ispolzovaniem Excel. Kyiv: Morion, 320.
  8. Gavrisyuk, V. K. (2016). Respiratornaya nedostatochnost: mehanizmy razvitiya, sposoby otsenki, oksigenoterapiya. Ukrayinskiy pulmonologichniy zhurnal, 4, 56–58.
  9. UnifIkovaniy klnichniy protokol pervinnoyi (vtorinnoyi) spetsializovanoyi, tretinnoyi (visokospetsializovanoyi) medichnoyi dopomogi tamedichnoy ireabilitatsii "Hronichne obstruktivne zahvoryuvannya legen" (2013). MOZ Ukrayini, No. 555. Pro zatverdzhennya standartizatsii medichnoi dopomogi pri HOZL. Available at: http://meduha.net/content/unifikovaniy-klinichniy-protokol-pervinnoyi-vtorinnoyi-specializovanoyi-tretinnoyi
  10. Jones, P. W., Adamek, L., Nadeau, G., Banik, N. (2012). Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification. European Respiratory Journal, 42 (3), 647–654. doi: 10.1183/09031936.00125612
  11. Gavrisyuk, V. K. (2006). Legochnaya nedostatochnost: mehanizmy razvitiya isposoby otsenki. Ukrayinskiy pulmonologichniy zhurnal, 3, 40–42.
  12. Celli, B. R., Cote, C. G., Marin, J. M., Casanova, C., Montes de Oca, M., Mendez, R. A. et. al. (2004). The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 350 (10), 1005–1012. doi: 10.1056/nejmoa021322
  13. Agusti, A., Edwards, L. D., Rennard, S. I., MacNee, W., Tal-Singer, R. et. al. (2012). Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype. PLoS ONE, 7 (5), e37483. doi: 10.1371/journal.pone.0037483
  14. Agusti, A. (2007). Systemic Effects of Chronic Obstructive Pulmonary Disease: What We Know and What We Don't Know (but Should). Proceedings of the American Thoracic Society, 4 (7), 522–525. doi: 10.1513/pats.200701-004fm
  15. Girdhar, A., Kumar, V., Singh, A., Menon, B., Vijayan, V. (2011). Systemic Inflammation and Its Response to Treatment in Patients With Asthma. Respiratory Care, 56 (6), 800–805. doi: 10.4187/respcare.00601
  16. Jousilahti, P., Salomaa, V., Hakala, K., Rasi, V., Vahtera, E., Palosuo, T. (2002). The association of sensitive systemic inflammation markers with bronchial asthma. Annals of Allergy, Asthma & Immunology, 89 (4), 381–385. doi: 10.1016/s1081-1206(10)62039-x
  17. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017. Available at: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/
  18. Avdeev, N. S. (2009). Klinicheskoe znachenie C-reaktivnogo belka pri HOBL. Meditsinskiy Vestnik, 18, 8–9.
  19. Higashimoto, Y., Iwata, T., Okada, M., Satoh, H., Fukuda, K., Tohda, Y. (2009). Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Respiratory Medicine, 103 (8), 1231–1238. doi: 10.1016/j.rmed.2009.01.021
  20. Groenewegen, K. H., Postma, D. S., Hop, W. C. J., Wielders, P. L. M. L., Schlösser, N. J. J., Wouters, E. F. M. (2008). Increased Systemic Inflammation Is a Risk Factor for COPD Exacerbations. Chest, 133 (2), 350–357. doi: 10.1378/chest.07-1342
  21. Barnes, P. J., Celli, B. R. (2009). Systemic manifestations and comorbidities of COPD. European Respiratory Journal, 33 (5), 1165–1185. doi: 10.1183/09031936.00128008

Downloads

Published

2017-07-31

How to Cite

Nazarenko, K. (2017). The role of comorbidity in the management of patients with combined pathology of asthma and copd. ScienceRise: Medical Science, (7 (15), 20–25. https://doi.org/10.15587/2519-4798.2017.108065

Issue

No. 7 (15) (2017)

Section

Medical Science

License

Copyright (c) 2017 Ksenia Nazarenko

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.